Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: VVOS 0 – 6 DCTH Matrix Metrics: VVOS 2 – 8 DCTH

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY).
  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both VVOS (36.4/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs DCTH
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$18.79
-2.34% 1D
Market Cap $669.3M
TTM Revenue $110M
Forward P/E 69.0x
Beta / 30D Vol 1.57β · 130% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $17.34 · SMA50: $16.22

6-Pillar Scorecard Institutional Category Breakdown (VVOS 0 – 6 DCTH)

Columns: Metric · VVOS · DCTH
1. Valuation Multiples DCTH
Forward P/E N/M 69.0x
Trailing P/E N/M 120.2x
PEG Ratio N/M 1.60x
EV / Revenue 0.1x 5.6x
2. Growth & Scale DCTH
Revenue Growth (YoY) +34.9% +70.7%
Earnings Growth (YoY) +0.0% +750.0%
TTM Revenue (USD) $21M $110M
Market Cap $1.9M $669.3M
3. Profitability & Quality DCTH
Gross Margin 61.9% 87.6%
Operating Margin -107.9% 5.2%
Net Profit Margin -121.8% 6.0%
Return on Equity (ROE) -8585.3% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) -$21M EBITDA $20M
Cash Flow Margin -99.3% EBITDA Mgn 18.3%
Net Cash / Leverage -8585.3% ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 64.8% (26th %ile)
Put/Call OI Skew N/A 0.22x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity N/A 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (2) vs DCTH (8)
Institutional Metric VVOS DCTH Criterion Row Edge
Market Capitalization
Scale
$1.9M $669.3M Larger Scale DCTH
Trailing P/E Ratio
Valuation
N/M 120.2x Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M 69.0x Lower Multiple DCTH
Revenue Growth (YoY)
Growth
+34.9% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
-107.9% 5.2% Higher Margin DCTH
Net Profit Margin
Profitability
-121.8% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-8585.3% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
0% ($0–$3) 74% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 1.57β · 130% Vol Lower Realized Risk VVOS
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 35.2 / 100 (SELL) Higher Composite VVOS
Trailing 12M Revenue (USD)
Operating Scale
$21M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev 1.60x PEG · 5.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +86.64 pp
VVOS: -59.25% · DCTH: +27.39%
3M Horizon DCTH +92.67 pp
VVOS: -80.49% · DCTH: +12.18%
6M Horizon DCTH +161.66 pp
VVOS: -91.15% · DCTH: +70.51%
1Y Horizon DCTH +218.51 pp
VVOS: -97.71% · DCTH: +120.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue DCTH Revenue VVOS Op. Margin DCTH Op. Margin Margin Leader
FY2015 N/A $0M N/A -870.6% DCTH
FY2019 $10M N/A -92.8% N/A VVOS
FY2020 $10M N/A -92.1% N/A VVOS
FY2021 $20M $0M -120.7% -690.0% VVOS
FY2022 $20M $0M -156.2% -1245.1% VVOS
FY2023 $10M $0M -125.3% -1849.0% VVOS
FY2024 $20M $40M -74.3% -33.4% DCTH
FY2025 $20M $90M -114.1% 0.8% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 64.8%
IV Percentile 26th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $669.3M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs DCTH Key Questions & Quantitative Answers

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both VVOS (36.4/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), VVOS cumulative revenue shifted +100.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

DCTH screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas DCTH trades at 69.0x Forward P/E, 120.2x Trailing P/E, 1.60x PEG, and 5.6x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, DCTH carries 64.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 130% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.